Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
4.800
+0.140 (3.00%)
At close: May 11, 2026, 4:00 PM EDT
4.700
-0.100 (-2.08%)
After-hours: May 11, 2026, 4:47 PM EDT
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$491,849
Profits / Employee
-$1,081,343
Market Cap
78.94M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 9 | -1 | -10.00% |
| Jun 30, 2024 | 10 | -1 | -9.09% |
| Jun 30, 2023 | 11 | -1 | -8.33% |
| Jun 30, 2022 | 12 | 1 | 9.09% |
| Jun 30, 2021 | 11 | -1 | -8.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| PolyPid | 75 |
| aTyr Pharma | 60 |
| eXoZymes | 32 |
| Q32 Bio | 24 |
| LeonaBio | 19 |
ATHE News
- 17 hours ago - Alterity Therapeutics publishes quantitative susceptibility mapping MRI data - TheFly
- 18 hours ago - Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy - GlobeNewsWire
- 4 days ago - Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 - GlobeNewsWire
- 11 days ago - Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update - GlobeNewsWire
- 13 days ago - Alterity Therapeutics Transcript: KOL event - Transcripts
- 14 days ago - Regulatory Update on Alterity Therapeutics (ATHE) and ATH434 Development - GuruFocus
- 14 days ago - Alterity Therapeutics Gets Positive FDA Feedback On ATH434 Phase 3 Study - Nasdaq
- 14 days ago - Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting - TheFly